Market Size of PAP and Paracetamol Industry
Study Period | 2019 - 2029 |
Base Year For Estimation | 2023 |
CAGR | 4.30 % |
Fastest Growing Market | Asia-Pacific |
Largest Market | North America |
Market Concentration | Medium |
Major Players*Disclaimer: Major Players sorted in no particular order |
PAP & Paracetamol Market Analysis
The PAP and Paracetamol Market is expected to register a CAGR of 4.3% during the forecast period.
The COVID-19 pandemic had a significant impact on the market. Paracetamol, due to its widespread availability, was recommended by various healthcare authorities around the world, such as the NICE, the NHS, the CDC, and the Ministry of Health and Family Welfare (MOHFW) of the GOI, for treating fever in adults and children with COVID-19. The COVID-19 pandemic initially created a tremendous demand for OTC analgesics, such as paracetamol, which led to restrictions on the export of essential drugs by local authorities to maintain sufficient stock in their country. However, as per the analysis, the exponential surge for analgesics created as a result of COVID-19 subsided owing to the lesser number of cases and availability of alternatives in the post-pandemic phase. On the other hand, the market is expected to grow at a stable pace over the analysis period due to the growing number of strategic initiatives and innovative product launches within the industry. For instance, in March 2022, Axunio developed Paraveganio, using 100% plant-based ingredients, and it is now the first product to be certified as vegan by The Vegan Society. Such product launches are expected to acquire an untapped population base, which may lead to the market's growth.
Factors such as the increasing prevalence of pain-related incidences and the advantages of para-aminophenol (PAP) and paracetamol over other analgesics are expected to increase the market's growth.
According to the article published in September 2021, the Interventional Pain and Spine Centre (IPSC) stated that 19% of the Indian adult population suffered from chronic pain of some kind, with a 25% prevalence in females. Thus, issues related to pain are major reasons for the use of analgesics for self-medication. Similarly, in order to counter such pain-related conditions, various companies are undertaking organic and inorganic strategic developments, including product launches, mergers and acquisitions, joint ventures, and product developments, among others. For instance, in June 2021, Bayer launched 10 brands, including the relaunch of the headache relief medicine Saridon in India. The relaunch will help Bayer grow its over-the-counter business in developing regions.
Moreover, paracetamol has various advantages over other analgesics. For instance, in March 2022, an article published in Informa UK Limited stated that people worldwide use paracetamol (acetaminophen) more than any other analgesic; besides being readily available over-the-counter (OTC), its popularity rests on being generally well tolerated and considered safer than other analgesics when taken as directed, especially in high-risk users such as older people or adults with comorbidities.
Thus, such advantages of paracetamol, coupled with an increased prevalence of pain-related incidences, are expected to accelerate the market's growth over the forecast period. However, the adverse effects of drugs are expected to hinder the market's growth.
PAP & Paracetamol Industry Segmentation
PAP and paracetamol are the most widely used analgesics and antipyretics that relieve pain and reduce fever.
The PAP and Paracetamol Market is Segmented by Dosage Form (Powder and Granules), Application (Tablet Drug, Granules Drug, Oral Solutions, and Other Applications), and Geography (North America (United States, Canada, and Mexico), Europe ) Germany, United Kingdom, France, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia-Pacific), Middle East and Africa (GCC, South Africa, and the Rest of Middle East and Africa), and South America Brazil, Argentina, and Rest of South America)). The report offers value (in USD million) for the above segments.The market report also covers the estimated market sizes and trends for 17 countries across major global regions. The report offers the value (in USD million) for the above segments.
By Type | |
Powder | |
Granules |
By Application | |
Tablet Drug | |
Granules Drug | |
Oral Solutions | |
Other Applications |
By Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
PAP and Paracetamol Market Size Summary
The PAP and Paracetamol Market is poised for steady growth, driven by strategic initiatives and innovative product launches. The COVID-19 pandemic initially spiked demand for paracetamol, as it was widely recommended for fever management, leading to export restrictions to maintain local stock. However, post-pandemic, the demand stabilized with the availability of alternatives. The market is expected to expand due to the increasing prevalence of pain-related conditions and the advantages of paracetamol over other analgesics, such as its widespread availability and safety profile. Companies are actively engaging in strategic developments, including product launches and partnerships, to capture untapped market segments. Notable product introductions, like Axunio's vegan-certified Paraveganio, exemplify the industry's focus on catering to diverse consumer preferences.
The tablet drug segment is anticipated to capture a significant market share, bolstered by the high prevalence of flu and the popularity of these formulations. The United States, with its robust healthcare infrastructure and high incidence of migraines and headaches, is expected to lead the market, supported by regulatory approvals for new products like Hyloris Pharmaceuticals' Maxigesic IV. North America's dominance is further reinforced by the presence of key industry players and the region's established healthcare systems. The market's competitive landscape features major players such as Cipla Inc., Dr. Reddy's Laboratories Ltd, and GlaxoSmithKline plc, who are actively expanding production capacities and product offerings to meet growing demand.
PAP and Paracetamol Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Increasing Prevalence of Pain Related Incidences
-
1.2.2 Advantages over Other Analgesics
-
-
1.3 Market Restraints
-
1.3.1 Adverse Effects of Drugs
-
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size by Value in USD million)
-
2.1 By Type
-
2.1.1 Powder
-
2.1.2 Granules
-
-
2.2 By Application
-
2.2.1 Tablet Drug
-
2.2.2 Granules Drug
-
2.2.3 Oral Solutions
-
2.2.4 Other Applications
-
-
2.3 By Geography
-
2.3.1 North America
-
2.3.1.1 United States
-
2.3.1.2 Canada
-
2.3.1.3 Mexico
-
-
2.3.2 Europe
-
2.3.2.1 Germany
-
2.3.2.2 United Kingdom
-
2.3.2.3 France
-
2.3.2.4 Italy
-
2.3.2.5 Spain
-
2.3.2.6 Rest of Europe
-
-
2.3.3 Asia Pacific
-
2.3.3.1 China
-
2.3.3.2 Japan
-
2.3.3.3 India
-
2.3.3.4 Australia
-
2.3.3.5 South Korea
-
2.3.3.6 Rest of Asia-Pacific
-
-
2.3.4 Middle East and Africa
-
2.3.4.1 GCC
-
2.3.4.2 South Africa
-
2.3.4.3 Rest of Middle East and Africa
-
-
2.3.5 South America
-
2.3.5.1 Brazil
-
2.3.5.2 Argentina
-
2.3.5.3 Rest of South America
-
-
-
PAP and Paracetamol Market Size FAQs
What is the current PAP and Paracetamol Market size?
The PAP and Paracetamol Market is projected to register a CAGR of 4.30% during the forecast period (2024-2029)
Who are the key players in PAP and Paracetamol Market?
Cipla Inc, Dr. Reddy’s Laboratories Ltd, GlaxoSmithKline plc and Sanofi are the major companies operating in the PAP and Paracetamol Market.